217 related articles for article (PubMed ID: 18089451)
1. Salivary phosphate secretion in chronic kidney disease.
Savica V; Calò L; Santoro D; Monardo P; Granata A; Bellinghieri G
J Ren Nutr; 2008 Jan; 18(1):87-90. PubMed ID: 18089451
[TBL] [Abstract][Full Text] [Related]
2. A new approach to the evaluation of hyperphosphatemia in chronic kidney disease.
Savica V; Calò LA; Granata A; Caldarera R; Cavaleri A; Santoro D; Monardo P; Savica R; Muraca U; Bellinghieri G
Clin Nephrol; 2007 Oct; 68(4):216-21. PubMed ID: 17969488
[TBL] [Abstract][Full Text] [Related]
3. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Salivary glands: a new player in phosphorus metabolism.
Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
[TBL] [Abstract][Full Text] [Related]
6. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.
Savica V; Calò LA; Caldarera R; Cavaleri A; Granata A; Santoro D; Savica R; Muraca U; Mallamace A; Bellinghieri G
Nephron Physiol; 2007; 105(3):p52-5. PubMed ID: 17220638
[TBL] [Abstract][Full Text] [Related]
7. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
[TBL] [Abstract][Full Text] [Related]
8. [Management of hyperphosphatemia in patients with chronic kidney disease].
Savica V; Santoro D; Monardo P; Mallamace A; Bellinghieri G
G Ital Nefrol; 2009; 26 Suppl 46():58-61. PubMed ID: 19644820
[TBL] [Abstract][Full Text] [Related]
9. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum phosphate predicts mortality in renal transplant recipients.
Connolly GM; Cunningham R; McNamee PT; Young IS; Maxwell AP
Transplantation; 2009 Apr; 87(7):1040-4. PubMed ID: 19352125
[TBL] [Abstract][Full Text] [Related]
11. Nail disorders in patients with chronic renal failure and undergoing haemodialysis treatment: a case-control study.
Dyachenko P; Monselise A; Shustak A; Ziv M; Rozenman D
J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):340-4. PubMed ID: 17309455
[TBL] [Abstract][Full Text] [Related]
12. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
Cupisti A; D'Alessandro C; Baldi R; Barsotti G
J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
[TBL] [Abstract][Full Text] [Related]
13. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.
Lee CT; Tsai YC; Ng HY; Su Y; Lee WC; Lee LC; Chiou TT; Liao SC; Hsu KT
J Ren Nutr; 2009 May; 19(3):220-7. PubMed ID: 19243976
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients.
Yokum D; Glass G; Cheung CF; Cunningham J; Fan S; Madden AM
J Ren Nutr; 2008 Nov; 18(6):521-9. PubMed ID: 18940656
[TBL] [Abstract][Full Text] [Related]
15. Oxalic Acid as a uremic toxin.
Mydlík M; Derzsiová K
J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441
[TBL] [Abstract][Full Text] [Related]
16. Calcium exposure and removal in chronic hemodialysis patients.
Sigrist M; McIntyre CW
J Ren Nutr; 2006 Jan; 16(1):41-6. PubMed ID: 16414440
[TBL] [Abstract][Full Text] [Related]
17. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
[TBL] [Abstract][Full Text] [Related]
18. Salivary beta2-microglobulin analysis in chronic kidney disease and hemodialyzed patients.
Michelis R; Sela S; Ben-Zvi I; Nagler RM
Blood Purif; 2007; 25(5-6):505-9. PubMed ID: 18187941
[TBL] [Abstract][Full Text] [Related]
19. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM; Farmer B; Smits G; Chonchol M
J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
[TBL] [Abstract][Full Text] [Related]
20. [CA-P control in haemodialysis and K/DOQI guidelines].
Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
